Page 38 - ITPS-8-3

INNOSC Theranostics and
Pharmacological Sciences Benzodiazepine use and retention in OAT

14. Torres-Lockhart KE, Lu TY, Weimer MB, Stein MR, opioid and benzodiazepine combination use. Drug Alcohol
Cunningham CO. Clinical management of opioid Depend. 2012;125(1-2):8-18.
withdrawal. Addiction. 2022;117(9):2540-2550.
doi: 10.1016/j.drugalcdep.2012.07.004
doi: 10.1111/add.15818
25. Bharat C, Gisev N, Barbieri S, et al. Prescription opioid
15. Carswell N, Angermaier G, Castaneda C, Delgado F. use among people with opioid dependence and concurrent
Management of opioid withdrawal and initiation of benzodiazepine and gabapentinoid exposure: An analysis
medications for opioid use disorder in the hospital setting. of overdose and all-cause mortality. Int J Drug Policy.
Hospital Pract (1995). 2022;50(4):251-258. 2024;123:104287.
doi: 10.1080/21548331.2022.2102776 doi: 10.1016/j.drugpo.2023.104287
16. Taylor JL, Wakeman SE, Walley AY, Kehoe LG. Substance 26. Macleod J, Steer C, Tilling K, et al. Prescription of
use disorder bridge clinics: Models, evidence, and future benzodiazepines, z-drugs, and gabapentinoids and
directions. Addict Sci Clin Pract. 2023;18(1):23. mortality risk in people receiving opioid agonist treatment:
doi: 10.1186/s13722-023-00365-2 Observational study based on the UK Clinical Practice
Research Datalink and Office for National Statistics death
17. Buresh M, Stern R, Rastegar D. Treatment of opioid use records. PLoS Med. 2019;16(11):e1002965.
disorder in primary care. BMJ. 2021;373:n784.
doi: 10.1371/journal.pmed.1002965
doi: 10.1136/bmj.n784
27. Olopoenia A, Camelo-Castillo W, Qato DM, et al. Adverse
18. Schmitz A. Benzodiazepine use, misuse, and abuse: A review. outcomes associated with concurrent gabapentin, opioid,
Ment Health Clin. 2016;6(3):120-126. and benzodiazepine utilization: A nested case-control study.
doi: 10.9740/mhc.2016.05.120 Lancet Reg Health Am. 2022;13:100302.
19. Bakouni H, Sharafi H, Drouin S, et al. Associations between doi: 10.1016/j.lana.2022.100302
buprenorphine\naloxone and methadone treatment and 28. DeHaan M, Radtke L, Hensley C, Hogue A. Determining efficacy
non-opioid substance use in prescription-type opioid use of intervention in the limitation of opioid and benzodiazepine
disorder: Secondary analyses from the OPTIMA Study: co-prescription. S D Med. 2020;73(10):480-483.
Associations entre le traitement avec la buprénorphine/
naloxone et avec la méthadone et l’utilisation de substances 29. Russell C, Law J, Bonn M, Rehm J, Ali F. The increase in
non opioïdes dans le trouble lié à l’usage d’opioïdes de type benzodiazepine-laced drugs and related risks in Canada:
sur ordonnance: Analyses secondaires de l’étude OPTIMA. The urgent need for effective and sustainable solutions. Int
Can J Psychiatry. 2024;69(4):252-263. J Drug Policy. 2023;111:103933.
doi: 10.1177/07067437231210796 doi: 10.1016/j.drugpo.2022.103933
20. Mahu IT, Conrod PJ, Barrett SP, Sako A, Swansburg J, 30. Andersen PA, Thomsen AH, Hasselstrøm JB, et al. Exploring
Stewart SH. The four-factor personality model and its death scenes and circumstances in fatal opioid poisonings:
qualitative correlates among opioid agonist therapy clients. Insights for preventive strategies using forensic autopsy cases
Front Psychiatry. 2023;14:1129274. in Western Denmark. Forensic Sci Int. 2024;356:111948.
doi: 10.3389/fpsyt.2023.1129274 doi: 10.1016/j.forsciint.2024.111948
21. Lei M, Rintoul K, Stubbs JL, et al. Characterization of bodily 31. Park TW, Saitz R, Ganoczy D, Ilgen MA, Bohnert AS.
pain and use of both prescription and non-prescription Benzodiazepine prescribing patterns and deaths from drug
opioids in tenants of precarious housing. Subst Use Misuse. overdose among US veterans receiving opioid analgesics:
2021;56(13):1951-1961. Case-cohort study. BMJ. 2015;350:h2698.
doi: 10.1080/10826084.2021.1958865 doi: 10.1136/bmj.h2698
22. Greenblatt DJ, Shader RI, Abernethy DR. Drug therapy. 32. U.S. Food and Drug Administration. FDA Drug Safety
Current status of benzodiazepines. N Engl J Med. Communication: FDA Urges Caution about Withholding
1983;309(7):410-416. Opioid Addiction Medications from Patients Taking
Benzodiazepines or CNS Depressants: Careful Medication
doi: 10.1056/nejm198308183090705
Management Can Reduce Risks. United States: U.S. Food and
23. Sanabria E, Cuenca RE, Esteso M, Maldonado M. Drug Administration; 2017.
Benzodiazepines: Their use either as essential medicines or 33. Eadie L, Lo LA, Christiansen A, et al. Duration of
as toxics substances. Toxics. 2021;9(2):25. neurocognitive impairment with medical cannabis use:
doi: 10.3390/toxics9020025 A scoping review. Front Psychiatry. 2021;12(286):638962.
24. Jones JD, Mogali S, Comer SD. Polydrug abuse: A review of doi: 10.3389/fpsyt.2021.638962

Volume 8 Issue 3 (2025) 32 doi: 10.36922/itps.5151